MedPath

Lidocaine Patch for Treatment of Persistent Inguinal Postherniorrhaphy Pain

Phase 3
Completed
Conditions
Inguinal Pain
Interventions
Registration Number
NCT01443325
Lead Sponsor
Rigshospitalet, Denmark
Brief Summary

In the present placebo-controlled cross-over study the researchers intend to investigate analgesic and sensory effects of a lidocaine patch in patients with severe persistent inguinal post-herniorrhaphy pain.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Male
Target Recruitment
21
Inclusion Criteria
  • Males > 18 yrs
  • ASA (American Society´s of Anesthesiology´s classification) scores I-III, with severe Pain for more than six months and with average daily pain intensities (numerical rating scale [NRS] 0-10 points) during rest or during movement > 6.
Exclusion Criteria
  • History of an allergic reaction or intolerance to amide local anesthetics or vehicle ingredients in the patches
  • Use of class I antiarrhythmic drugs (e.g., tocainide and mexiletine)
  • Severe cardiac impairment, e.g., NYHA (New York Heart Association) Class ≥ III
  • Inflamed or injured skin at the application site
  • Known severe hepatic disorder (Child-Pugh score > 6)
  • Known severe renal impairment, (creatinine clearance < 30 mL/min)
  • Signs of cognitive impairment or known drug or ethanol abuse during the last 2 years.

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
lidocaine patchlidocaine patch-
Primary Outcome Measures
NameTimeMethod
pain reduction with lidocaine patchassessed the last three days in each treatment period
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Rigshospitalet

🇩🇰

Copenhagen, Denmark

© Copyright 2025. All Rights Reserved by MedPath